GOPRELTO Drug Patent Profile

When do Goprelto patents expire, and when can generic versions of Goprelto launch?

Goprelto is a drug marketed by Lxo Ireland and is included in one NDA. There are twelve patents protecting this drug.

The generic ingredient in GOPRELTO is cocaine hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cocaine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Goprelto

Goprelto was eligible for patent challenges on December 14, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 7, 2037. This may change due to patent challenges or generic licensing.

There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GOPRELTO

US Patents:	12
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	2
Patent Applications:	630
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GOPRELTO
What excipients (inactive ingredients) are in GOPRELTO?	GOPRELTO excipients list
DailyMed Link:	GOPRELTO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GOPRELTO

NDA:

209963

Dosage:

SOLUTION;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GOPRELTO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Omnivium Pharmaceuticals LLC	PHASE3
Pharmaceutical Project Solutions, Inc.	Phase 4

See all GOPRELTO clinical trials

US Patents and Regulatory Information for GOPRELTO

GOPRELTO is protected by fifteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lxo Ireland	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes
Lxo Ireland	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes
Lxo Ireland	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes
Lxo Ireland	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes			Y
Lxo Ireland	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes
Lxo Ireland	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes

Market Dynamics and Financial Trajectory for GOPRELTO

Last updated: January 4, 2026

Executive Summary

GOPRELTO (generic name: remdesivir) is an antiviral treatment primarily targeted at severe COVID-19 cases. As a prominent agent during the pandemic, its manufacturing, regulatory approvals, and usage patterns significantly influence its market dynamics and financial trajectory. This analysis offers a comprehensive review of GOPRELTO's current position, growth drivers, challenges, competitive landscape, and future outlook.

Key insights:

• The global COVID-19 landscape continues to impact GOPRELTO demand, with evolving variants and vaccination rates influencing treatment protocols.
• Regulatory approvals have expanded, with numerous countries allowing GOPRELTO’s use, albeit with emerging off-label and generic competition.
• Revenue projections indicate a decline post-pandemic peaks but sustained demand due to emerging indications and broadening approval.
• Market players emphasize manufacturing scalability and supply chain resilience to optimize profitability.

1. Introduction to GOPRELTO

GOPRELTO (remdesivir), developed initially by Gilead Sciences, Inc., received emergency use authorization (EUA) and subsequent approval by major regulatory agencies including the FDA (2020) for treating COVID-19. Its mechanism inhibits viral RNA-dependent RNA polymerase, demonstrating activity against SARS-CoV-2.

Key Attributes:

Attribute	Details
FDA Approval	October 22, 2020 (full approval in 2023 for certain indications)
Indications	Hospitalized COVID-19 patients, some off-label uses
Formulation	Intravenous infusion
Pricing	Varies by provider, ranging from ~$520 to ~$3,120 per treatment course in the US

2. Market Dynamics

2.1. Current Market Size and Growth

Year	Estimated Global Revenue	Growth Rate (CAGR)	Source/Notes
2020	$1.2 billion	N/A	Peak pandemic demand
2021	$1.8 billion	50%	Increased global uptake
2022	$1.5 billion	-16.7%	Post-pandemic decline begun
2023*	$1.2 billion	Stable	Continued usage with new indications

*Forecast based on industry reports

2.2. Key Drivers

• Pandemic progression: Variants (Omicron, Delta) influence demand for GOPRELTO as treatment remains a critical intervention.
• Regulatory landscape: Emergency Use Authorization (EUA) and full approvals expand access.
• Hospital protocols: Adoption as standard of care in severe cases.
• Pricing and reimbursement policies: Reimbursement schemes in major markets influence revenue.

2.3. Challenges

• Emergence of new antiviral agents: Paxlovid (Pfizer), Molnupiravir (Merck) compete for market share.
• Limited efficacy in mild/moderate cases: Restricts broader use.
• Vaccine coverage: High vaccination rates reduce severe case incidences, decreasing GOPRELTO demand.

2.4. Competition and Substitutes

Competitor	Drug Name	Mechanism	Market Status	Price per Course	Notes
Pfizer	Paxlovid	Protease inhibitor	Approved globally	~$700	Oral, outpatient use
Merck	Molnupiravir	Nucleoside analog	Approved in some regions	~$700	Oral, outpatient
Gilead	Remdesivir (GOPRELTO)	RNA polymerase inhibitor	IV, inpatient	$520-$3120	Limited outpatient use

2.5. Geographic Market Analysis

Region	Market Share (%)	Key Trends	Regulatory Status
North America	~55%	Dominant due to early adoption	Fully approved, reimbursement robust
Europe	~25%	Growing use, regulatory approvals	EMA approved, national authorizations
Asia-Pacific	~10%	Emerging markets, supply chain challenges	Approvals varying, low penetration
Rest of World	~10%	Limited access, dependent on imports	Regulatory hurdles

3. Financial Trajectory

3.1. Revenue Estimates and Trends

• Pre-pandemic projections anticipated modest revenues (~$200-300 million annually for remdesivir) post-COVID.
• Pandemic-driven spikes surged revenue (~$1.8 billion in 2021), with recent stabilization.

• Future revenue depends on:

  • Indication expansion: Investigations into remdesivir for other viral infections (e.g., Nipah virus, Ebola).
  • Pricing strategies: Negotiations with payers and governments.
  • Market penetration of oral antivirals: Which may reduce inpatient IV use.

3.2. Cost Structure and Profitability

Cost Aspect	Estimated Range	Notes
Manufacturing	$150-$250 per course	High-volume, scale benefits
Distribution & Logistics	$50-$100	Supply chain expenses
R&D	Low (post-pandemic)	Limited, as current formulations are mature
Regulatory & Marketing	Variable	Focused on expanding indications

3.3. Profit Margins and Investment Outlook

• Gross margins are projected at 20-30% due to high manufacturing costs and competitive pricing.
• Margins could improve with increased scale and new indications.
• Investment in manufacturing capacity remains prioritized to meet global demand surges.

3.4. Financial Risks

Risk Factor	Impact	Mitigation Strategies
Declining demand	Revenue reduction	Diversify indications, develop oral formulations
Competitive pressure	Price erosion	Patent protections, downstream innovations
Regulatory delays	Market access issues	proactive engagement, expedited approvals

4. Regulatory and Policy Environment

4.1. Global Approvals

Authority	Approval Status	Conditions	Date
FDA (US)	Fully approved (2023)	For hospitalized COVID-19	October 2020 (EUA), 2023 (Full)
EMA (EU)	Conditional approval	Severe COVID-19	July 2020
Japan	Approved	Severe COVID-19	June 2020
China	Approved	Emergency use	2021

4.2. Reimbursement Policies

• US: CMS covers remdesivir for hospitalized COVID-19 patients.
• Europe: Reimbursement varies by country; generally favorable in public health systems.
• Emerging markets: reimbursement is inconsistent, often subsidized.

4.3. Future Policy Considerations

• Policies favor oral antivirals over IV treatments, potentially impacting GOPRELTO's market dominance.
• Global stockpiling and procurement contracts influence supply and pricing strategies.

5. Future Outlook

5.1. Growth Opportunities

• Indication expansion: ongoing trials for other viral diseases.
• Combination therapy: exploring synergistic effects.
• Formulation improvements: development of oral or long-acting formulations.
• Market penetration: especially in Asia-Pacific and low-income countries through licensing and partnerships.

5.2. Threats

• Market saturation: declining demand as COVID-19 transitions to endemic phase.
• Emerging competitors: novel antivirals with better efficacy or oral formulations.
• Regulatory hurdles: delays or restrictions affecting access.

5.3. Long-term Revenue Projection

Scenario	2025 Revenue Estimate	Assumptions
Bullish	~$800 million	Successful indication expansion, stable COVID-19 demand
Base	~$500 million	Maintenance of current indications, moderate COVID-19 prevalence
Bearish	<$300 million	Significant competition, reduced COVID-19 severity

Key Takeaways

• GOPRELTO experienced a revenue surge during the height of COVID-19 but faces declining demand as vaccination and new treatments evolve.
• Regulatory expansions and indication broadening are vital for maintaining positive financial trajectories.
• Competition from oral antivirals like Paxlovid and Molnupiravir constrains GOPRELTO’s market share; innovation and formulation improvements are essential.
• Manufacturing scalability and global procurement strategies influence profitability and supply resilience.
• The future market for GOPRELTO hinges on continuous adaptation to the shifting pandemic landscape and therapeutic innovations.

6. FAQs

Q1: Will GOPRELTO maintain its relevance in the post-pandemic world?
A: Its relevance depends on ongoing COVID-19 treatment protocols and its potential expansion into other viral therapies. The shift toward oral antivirals may limit inpatient IV treatment demand, unless GOPRELTO diversifies indications.

Q2: What are the main competitive advantages of GOPRELTO?
A: Established regulatory approval, proven efficacy in severe cases, and manufacturing capacity. However, oral formulations pose a significant competitive threat.

Q3: How do global policy differences impact GOPRELTO’s market?
A: Variations in approval and reimbursement influence market access and pricing, with high-income countries adopting it more broadly than low-income regions.

Q4: What are potential areas for innovation?
A: Developing oral, long-acting formulations, expanding indications, and combination therapies to enhance efficacy.

Q5: What is the outlook for GOPRELTO’s profitability over the next five years?
A: Expected to decline gradually unless new indications or formulations compensate for decreasing severe COVID-19 cases, with revenues stabilizing around $300-$800 million depending on developments.

---

References

1. Gilead Sciences. Remdesivir (GOPRELTO) Product Information. 2023.
2. U.S. Food & Drug Administration. Remdesivir EUA and FDA Approval. 2020-2023.
3. European Medicines Agency. Regulatory Authorizations for Remdesivir. 2020-2023.
4. MarketsandMarkets. COVID-19 Therapeutics Market Analysis. 2022.
5. IQVIA. Global Pharmaceutical Market Data. 2022.